Background--People with end-stage renal disease (ESRD) are at risk for advanced heart failure, but little is known about use and outcomes of durable mechanical circulatory support in this setting. We examined use and outcomes of implantable ventricular assist devices (VADs) in a national ESRD cohort.
function requirements for LVAD placement. 8 Several recent publications address long-term dialysis management in people with LVADs, although this is often in the context of ESRD developing after LVAD implantation. 9 With advancing technologies, management challenges change. Continuous flow devices, now used almost exclusively, are less preload dependent than the earlier pulsatile flow devices, 10 perhaps making volume shifts with ultrafiltration in hemodialysis less concerning. However, they are associated with more gastrointestinal bleeding and cerebrovascular events. 11,12 ESRD and VADs may have overlapping and negatively synergistic risk profiles, related to bleeding complications, infections, and neurologic dysfunction. Organizations and authors are increasingly advocating for an integrated palliative care approach to the care of people with advanced heart failure, given their substantial symptom burden and high mortality. An American Heart Association scientific statement suggests routine palliative care physician consultation before institution of mechanical circulatory support, and The Joint Commission requires palliative care specialist involvement for VAD destination therapy. [13] [14] [15] Organizations and authors are also increasingly recognizing the important role palliative care plays in ESRD, and especially congestive heart failure complicating ESRD. 16, 17 People with ESRD, and those with congestive heart failure, may receive lower quality end-of-life care than those with other life-limiting conditions. 18 We aimed to describe implantable VAD use among Medicare beneficiaries with ESRD, and their hospitalizations and survival. We hypothesized that mortality would decrease in more recent years and would vary between people who were receiving dialysis and those with kidney transplants. We investigated the use of implantable VADs in Medicare beneficiaries with ESRD, including dialysis-dependent people (CKD 5D) and kidney transplant recipients (CKD T), using data from the United States Renal Data System (USRDS).
Methods
The data files are publicly available from the USRDS. The analytic methods and study materials will not be maintained in a publicly available repository for other researchers to reproduce the results or replicate the procedure.
Study Population
We identified Medicare beneficiaries with ESRD 19 We identified implantable VAD placement using Medicare Part A institutional claims with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure code 37.66 (insertion of implantable heart assist system). The claims also had to include diagnoses for HF or cardiogenic shock, in which case it was classified as primary therapy, or there had to be a claim within 30 days prior for a separate major cardiac surgery, in which case it was classified as post-cardiotomy (Table S1) . 20, 21 In 2005, before our study period, ICD-9-CM procedure codes were refined to distinguish implantable (37.66) and non-implantable (37.62 and 37.65) ventricular assist devices. 20 We required the VAD index date to be >30 days after the ESRD index date, which was obtained from the ESRD Medicare Evidence Report (Centers for Medicare & Medicaid Services Form 2728). People who recovered kidney function before VAD implantation were excluded (n=24). Transplantation was identified from Medicare institutional claims with ICD-9-CM 37.51 (heart transplantation), or USRDS reported kidney transplantation event, which is based on Organ Procurement and Transplantation Network data. People were excluded from the cohort if they had heart transplantation within 30 days before, or on the same day of, the VAD implantation. We determined hemodialysis vascular access at time of VAD implantation using the Medical Evidence Report, Medicare procedural claims, and, for VAD implantation since
Clinical Perspective
What Is New?
• People with end-stage renal disease (ESRD) are at risk for advanced heart failure, but little is known about use and outcomes of durable mechanical circulatory support in this setting.
• Using Medicare data, the current study demonstrates that ventricular assist devices are being implanted in people with pre-existing ESRD, sometimes several years after incident ESRD.
• These people have high in-hospital and 1-year mortality.
What Are the Clinical Implications?
• Clinicians should be aware of the high mortality among Medicare beneficiaries with ESRD who undergo ventricular assist device implantation.
• Investigations are needed to improve outcomes of people with ESRD who require mechanical circulatory support for advanced heart failure.
July 2010, the Centers for Medicare & Medicaid Services Common Procedure Coding Standard (HCPCS) modifier codes from the Revenue Center Details Files.
Predictors
We divided VAD implantation years into ranges (2006-2009, 2010-2011, and 2012-2014) , to reflect changing patterns of device technology and experience (eg, changes in device strategy from use as a bridge to heart transplantation in the earlier years, to use as destination therapy also in later years 
Outcomes
We identified all-cause mortality from the USRDS database, which combines death identification from several sources. 19 In-hospital mortality was identified by comparing hospitalization dates and dates of death. Duration of hospitalization was determined using Medicare claims. Hospitalizations with discharges followed by admission on the same day were counted as 1 hospitalization. Proportion of days hospitalized in the first year following the VAD implantation was calculated by the total number of days of hospitalization divided by the days before death, heart or heart-kidney transplantation, or loss of Medicare Parts A and B coverage. Among patients discharged alive from the initial hospitalization and having continuous Medicare Parts A and B, we determined readmission causes by classifying the primary discharge diagnosis using the Healthcare Cost and Utilization Project Clinical Classification Software for most causes. 24 Infection-related readmissions were determined from the primary discharge diagnosis, using ICD-9-CM codes as outlined in Table S2 . 25 
Covariates
We extracted demographic data from the USRDS Patients file. We identified comorbid conditions from inpatient and outpatient claims submitted to the Centers for Medicare and Medicaid Services within 2 years before VAD implantation (as early as 2004), among the subgroup of those with continuous Medicare Parts A and B coverage during that time, using ICD-9-CM diagnostic codes (Table S1 ). We verified that the ICD-9-CM codes used did not change substantively between 2004 and 2014. We obtained the cause of ESRD from the Medical Evidence Report.
Statistical Methods
Characteristics at the time of VAD implantation were described as mean (SD) or median (interquartile range) for continuous variables, and as number (%) for categorical variables. Descriptive statistics are provided for the overall cohorts, and for subgroups by ESRD modality and VAD implantation year. Subjects were right censored when they lost continuous Medicare Parts A and B coverage or survived 1 year after VAD implantation, whichever was earlier. Heart and/or kidney transplantation were considered as competing events. Cumulative mortality incidence in 1 year after VAD implantation was estimated considering competing events and compared between subgroups using Gray's test. 26 Baseline factors hypothesized to be associated with mortality (age, dichotomized race, sex, cause of ESRD [diabetes mellitus or other], year-range of VAD implantation, and implantation circumstance [primary or post-cardiotomy]) were evaluated using univariable and multivariable cause-specific hazards regression models and subdistribution hazard models, using transplantations as competing events, and are reported with hazard ratios (HR) and 95% confidence intervals. We limited the number of variables in the models to avoid overfitting. Readmission was calculated using cumulative incidence of first readmission over 1 year, with competing events of death and transplantation, among patients with continuous Medicare Parts A and B who survived the index hospitalization. We created a competing events graph for those on maintenance dialysis at VAD implantation, demonstrating the proportions alive on dialysis, transplanted, and deceased, over 1 year. We conducted the analyses using SAS 9.4 (SAS Institute, Cary, NC). Two-sided significance at a=0.05 was used in all analyses. This study was approved by the Institutional Review Board at Baylor College of Medicine (protocol #H-36408). Informed consent was waived.
Results

Patient Characteristics
We identified 96 people with ESRD who underwent VAD implantation (Tables 1 and 2 ). Seventy-four people (77.1%) were on hemodialysis, 10 (10.4%) were on peritoneal dialysis, and 12 (12.5%) had a functioning kidney transplant at time of VAD implantation. Age at VAD implantation ranged from 25 to 80 years old, and mean (SD) age at implantation was 56.8 (12.5) years. Females made up 21.9% of the cohort, with similar sex distributions in subgroups based on ESRD modality. Most of the cohort was classified as white, and approximately one third of the cohort was black. Diabetes mellitus was the most common cause of ESRD. Time from incident ESRD to VAD implantation ranged from 0.1 to 27.6 years. Among those with kidney transplants, the interval was longer (median [interquartile range] 14.5 [8.4, 21.2] years), compared with those on hemodialysis or peritoneal dialysis (3.7 [0.9, 6.6] years) ( Table 2 ). In each modality and era subgroup, >55% underwent VAD implantation for primary indications, except the 2006 to 2009 era, in which 44.7% had a primary indication (Table 2) . Among those on maintenance hemodialysis at time of VAD implantation, 43.3% used a dialysis catheter, 41.9% used an arteriovenous dialysis access (fistula or graft), and 14.9% used unknown dialysis access.
Mortality and Transplantation
Mortality rates were high early after implantation, and subsequently declined (Figure 1 ). Thirty-nine people (40.6%) died during the VAD implantation hospitalization, with similar in-hospital mortality in the dialysis and kidney transplant subgroups. An additional 20 people died within 1 year of VAD implantation, for a total 1-year mortality of 61.5%. This proportion did not vary significantly by whether the patient was receiving maintenance hemodialysis, peritoneal dialysis, or had a functional kidney transplant at time of implantation. Cumulative 1-year mortality incidence was 48.4% in the primary implantation group, compared with 73.8% in the postcardiotomy group (P=0.003), due primarily to early mortality events ( Figure S1 ). For the most recent VAD implantations (2012-2014), 1-year cumulative mortality was 51.5%, compared with 63.4% in 2006 to 2009 (P=0.11). We also analyzed 1-year cumulative mortality by the interval from incident ESRD to VAD implantation, dichotomized at 1 year, and found similar outcomes (interval <1 year: 61.7%, interval ≥1 year: 59.0%).
In (Table S3 ). Figure 2 shows the proportions of the initial cohort that remained alive and on dialysis, had received transplants, or had died before receiving transplants, over the first year following VAD implantation. Among those with CKD 5D at the time of VAD implantation, by 1 year following VAD implantation, 10.4% had received transplantation, and 30.2% remained on dialysis.
Duration of Hospitalizations
Among those who survived the initial hospitalization, the time from VAD implantation until discharge was median (interquartile range) 27.5 (12.5, 48.5) days, with a maximum interval of 251 days. The proportion of the first year (mean [SD]) 
All-Cause and Cause-Specific Readmissions
Of the 43 people who survived the initial hospitalization and had continuous Medicare coverage, 38 (88.4%) had at least 1 readmission during the first year. The most common readmission causes during the first year were cardiovascular (62.8% of people had a cardiovascular readmission), infection (51.5%), and gastrointestinal or other non-intracranial hemorrhage (30.3%).
Discussion
In this national cohort of people with ESRD, on either maintenance dialysis or with functioning kidney transplant, who received implantable VAD placement, we found that over half the patients died within 1 year. This cohort consisted of people with severe organ dysfunction, requiring dual organ support therapy, and as such, high mortality is expected. Nearly half the cohort underwent post-cardiotomy implantation, which generally has higher mortality, and in our cohort had 77% higher mortality risk than primary implantation, although this did not reach statistical significance in multivariable analysis. We found that males had much lower mortality risk than females after VAD implantation, a pattern previously reported in non-CKD LVAD cohorts. 27 The hemodynamic instability and clinical status at time of implantation, as reflected by the Interagency Registry for Mechanically Assisted Circulatory Support (INTER-MACS) profile, is an important determinant of mortality, 27 and is unknown in our cohort. It is likely, however, that the severe chronic kidney disease and associated comorbidities are major contributors to the high mortality. Data from INTERMACS, a national database of people receiving VAD implantation, show much higher survival than our cohort, with 1-year survival of 81% in continuous flow LVADs and 65% with pulsatile flow LVADs in 2006 to 2013. 22 Bansal et al recently published an analysis of circulatory support use in people with ESRD from 2003 to 2013, based on Medicare claims. 28 However, unlike our analysis, that analysis included both external circulatory support devices (ICD-9-CM 37.62 and 37.65) and implantable VADs. 28, 29 Thus, temporary circulatory support devices were included, which have different indications and outcomes than durable VADs, including placement in dire circumstances such as acute cardiogenic shock or cardiopulmonary arrest. 30 This may in part explain the higher reported in-hospital mortality (51.6%) compared with our cohort (40.6%). Further, primary and postcardiotomy mechanical circulatory support were not distinguished in that report. Other publications on VADs in ESRD are limited to case reports and small case series. 31, 32 Arteriovenous hemodialysis accesses, which divert a significant portion of the cardiac output from systemic perfusion and have been implicated in high-output HF, have been a cause for concern, both in terms of whether maturation would occur for arteriovenous fistulas, and whether systemic perfusion would remain adequate. 33, 34 Recent case reports have described successful arteriovenous fistulas maturation in hemodialysis patients with LVADs. 35, 36 A large proportion of our patients had arteriovenous accesses at time of VAD implantation, but we were unable to investigate outcomes related to dialysis access because of limited numbers. Kidney dysfunction at time of LVAD implantation is associated with worse outcomes in other cohorts, although in those cases the dysfunction may reflect the severity of cardiac decompensation, and may be primarily acute. 6, 22, 37 Many other investigations have focused on acute kidney injury complicating the LVAD implantation procedure, and on postimplantation reductions in estimated glomerular filtration rate, and both are associated with poor outcomes. 38 Preimplantation proteinuria has recently been reported to be associated with mortality and need for renal replacement therapy among people receiving LVADs, which may reflect presence of parenchymal kidney disease and endothelial dysfunction. 39 Our cohort included exclusively people with chronic kidney failure. To be included a nephrologist had to formally certify, at least 30 days before VAD implantation, that the patient had irreversible kidney failure requiring dialysis or kidney transplantation. For most of our cohort, the ESRD declaration antedated the VAD implantation by several years. The age and preexisting comorbidities reflect the expected case-mix in a group with end-stage heart and kidney disease. Diabetes mellitus is the most common cause of ESRD, and was the most common cause of ESRD among our cohort. Diabetes mellitus itself is associated with higher mortality and other adverse outcomes with VADs (including stroke, pump thrombosis, and device infection). 21, 40 As VADs are more commonly used, they are being implanted in people with higher comorbidity burden. Because VAD placement in people with ESRD is not routine practice, the people in our cohort may have been carefully selected based on clinician expectation of recovery and lifeprolongation and placed in high-volume centers comfortable with more complicated patients, factors which would make the observed high mortality more concerning. The decreased mortality risk point estimate in more recent years mirrors improvements that have been reported in the non-CKD VAD population. 41 The decreasing mortality observed in the non-CKD VAD population, likely because of improved technology and increasing experience with care of these patients, may be carrying over to people with ESRD. In If clinicians consider VAD implantation in a person with ESRD, given the prolonged hospitalizations, frequent complications and readmissions, and substantial mortality observed in our study, integrated palliative care, with close cooperation with a palliative care physician, is essential.
This analysis is the largest to our knowledge of people with ESRD who receive exclusively implantable VADs and is based on a national sample. The USRDS data set, with information on many people with ESRD, allowed for the analysis of a procedure that is not routine in this population. As such, it expands current knowledge. Nevertheless, there are important limitations. As it is based on administrative data, we are unable to determine details of devices and clinical circumstances. We are also unable to confirm that all patients underwent LVAD implantation; however, given the rarity of biventricular or right VADs, this is likely the case. We are also unable to confirm that these were the first VAD implantations, rather than device replacement, in all people. However, most had Medicare coverage before implantation, and among these we confirmed that there were no prior VAD implantations. Finally, because placement of VADs in people with ESRD remains uncommon, the cohort was small, and thus adjustment for potentially important comorbidities was limited. Despite this, this is the largest description to date of implantable VAD use in people with existing ESRD.
Conclusion
Implantable VAD placement in Medicare beneficiaries with ESRD is associated with high in-hospital and 1-year mortality, and readmissions. These risks may have improved in recent years, because of VAD technology improvements. Combined heart and kidney disease is a vexing problem, and people with ESRD and severe HF who undergo VAD implantation are among the most profoundly ill people. Our investigation highlights the need for further studies to determine optimal management of these coexisting conditions. LVAD implantation circumstance: Primary Post-cardiotomy
